Related Experiment Video
Updated: Jun 5, 2026
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
Recent developments in prostate cancer biomarker research: therapeutic implications
Sujitra Detchokul1, Albert G Frauman
1Clinical Pharmacology and Therapeutics Unit, Department of Medicine (Austin Health/Northern Health), the University of Melbourne, Heidelberg, Victoria 3084, Australia.
Abstract:
This review aims to present an overview of recent clinical trials targeting biomarkers in advanced prostate cancer. We searched ClinicalTrials.gov for early phase clinical trials on treatments of prostate cancer that have been recently completed, are ongoing or are actively recruiting participants. Drug targets and their mechanism of actions were assessed and summarized. Trials were categorized according to prostate cancer biomarkers that have potential as therapeutic targets. A total of 19 new therapeutic agents for the treatment of prostate cancer are included in this review. Trials are summarized according to the targeted biomarkers and are categorized into five therapeutic approaches: prostate cancer vaccine, epigenetic therapy, pro-apoptotic agents, prostate cancer antibodies and anti-angiogenesis approach. Some of the therapeutic agents reviewed showed promising results, warranting further investigation in late phase clinical trials. Recent novel prostate cancer biomarkers that made it through clinical trials and their relevance as drug targets are summarized. This review emphasizes the importance of specific prostate cancer biomarkers and their potentials as targets of the disease. Some clinical trials of targeted treatments in prostate cancer show promising results. Better understanding of disease mechanisms should potentially lead to more specific treatments for individual patients.
Insights
This review highlights 19 new agents targeting advanced prostate cancer biomarkers. Promising early trial results suggest potential for more personalized treatments through biomarker-driven therapies.
Area of Science:
- Oncology
- Clinical Pharmacology
Background:
- Advanced prostate cancer treatment relies on identifying effective therapeutic targets.
- Biomarkers play a crucial role in guiding the development of targeted therapies.
Purpose of the Study:
- To review recent early-phase clinical trials targeting biomarkers in advanced prostate cancer.
- To summarize novel therapeutic agents and their mechanisms of action.
- To categorize trials based on targeted biomarkers and therapeutic approaches.
Main Methods:
- Searched ClinicalTrials.gov for completed, ongoing, and recruiting early-phase prostate cancer trials.
- Assessed and summarized drug targets and mechanisms of action.
- Categorized trials by targeted biomarkers and therapeutic strategies.
Main Results:
- Included 19 new therapeutic agents for advanced prostate cancer.
- Categorized agents into five approaches: vaccine, epigenetic, pro-apoptotic, antibody, and anti-angiogenesis.
- Observed promising results for several agents, suggesting further investigation.
Conclusions:
- Specific prostate cancer biomarkers are vital for developing targeted treatments.
- Biomarker-driven therapies show promise for more personalized patient care.
- Understanding disease mechanisms is key to advancing prostate cancer treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...